

# Company Profile\* Today's Abdi Ibrahim

Shareholders The Barut and Esirtgen Families

Abdi Ibrahim Tower Istanbul, Turkey

Production and R&D Esenyurt, Istanbul

Turnover 480 Million USD

Production Capacity 350 Million Units

Product Range 56% Original Pharmaceuticals

44% Generic Pharmaceuticals

Licensors ~ 30 International Companies

Employees ~ 3.000


\* As of December 2015







### **Turkish Pharmaceutical Market Development**









### **Abdi İbrahim Market Share in Turkey**

#### Market Share - Units (2015)



#### Market Share - \$ Turnover (2015)



Ref: IMS





### Abdi İbrahim is strategically present in 6 countries



#### **Production Facilities**



#### Algeria (under construction)

Production Capacity	12 million boxes
Total Closed Area	6.000 sqm
Production Area	5.500 sqm
Employees	> 80
Pharmaceutical Forms	Solid and liquid



#### Kazakhstan

Production Capacity	8 million boxes
Total Closed Area	11.600 sqm
Production Area	7.000 sqm
Employees	> 70
Pharmaceutical Forms	Solid dosages

### **Abdi İbrahim in the World\***

Abdi Ibrahim Affiliates (Own companies, factories, sales forces)					
Algeria	Azerbaijan	Albania			
Kazakhstan	Georgia	Iraq			
Other Countries (O	peration through distributo	r, products sold with Abdi İb	rahim Brands)		
GCC	UK	Germany	Afganistan		
Jordan	Netherlands	Czech Republic	Portugal		
Libya	Bosnia	Turkmenistan	Yemen		
Kosova					
Out-licensing Coun	tries (products developed a	at Abdi İbrahim but sold with	customer brands)		
EU Countries	Canada	Lebanon	S.Korea		
Russia	Tunisia	Belarusia	Colombia		
Ukraine	Morocco	S.Africa			

Turnover: \*63 million USD

\* ≈ 2015 annual gross turnover










International Markets

### The Worldwide availability of Abdi Ibrahim Registered **Products** \*



- **■**BALKANS
- MENA & Sub-Saharan Africa
- EU
- CANADA
- FAR EAST



\*number of MAs







## R&D, Manufacturing & Licensing (Capabilities)



**ABDI**IBRAHIM

International Markets



#### R&D Excelence



The first and the largest accredited R&D center in Turkish Pharma Industry

5% of turnover allocated to R&D activities

Advantageous location for "Day1" launches in EU

Experience in conducting co-development projects with several European companies and worlwide experience in registration


WHO's GMP standards are used in studies conducted with state of the art equipments

Innovative approaches to design formulations and manufacturing processes (industry leader in patent applications)





International Markets





#### Manufacturing Excelence



Experience in manufacturing of nearly 200 molecules in solid, semi-solid, liquid galenic forms

Annual capacity of 350 million packs in Turkey

BfarM, Danish Medicine Agency, GCC, Canada, Ukraine, MCC, Infarmed, Korea and several other authority and customer audits and approvals

Experience in manufacturing with deadlines and making "Day 1 launches" for off-patent products

Supply to 50 countries including several EU states with several SKUs



#### Manufacturing Excelence



Compliance with special authority needs in terms of packaging (Bollino, 2d barcoding, vignette etc.)

Support in providing stability studies in different climatic zones

Production possibilities such as multilayer tablets, sachets & efervescants

Flexibility in lead times


The largest and brand-new technologistic center in Turkish Pharma Industry (35M USD invested)

Current manufacturing capability in Kazakhistan & Turkey & Algeria Soon biotech manufacturing option in Turkey





#### Licensing Excelence



Direct out-licensing deals with multinational companies like Mylan, Stada, Sanofi, Aspen and deals with local leaders like Pharmaline, Teriak, Bottu, Propharma & Delta Medical, Camox, Tchaikapharma, Dr. Max Pharma, Orifarm, Banaja, Mint & Riva

Runed several DCPs for EU & Canada, product under registration in GCC

Decades of experience in working with licensores & possible synergies

Out-licensing department with dedicated key account managers